The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trialChristopher G. Davey, Michael Berk, Andrew M. Chanen et al.|The Lancet Psychiatry|2019Cited by 109
Broad clinical high‐risk mental state (CHARMS): Methodology of a cohort study validating criteria for pluripotent riskJessica Hartmann, Patrick D. McGorry, Barnaby Nelson et al.|Early Intervention in Psychiatry|2017Cited by 105
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?Seetal Dodd, Michael Berk, Michael Bauer et al.|The World Journal of Biological Psychiatry|2020Cited by 88
Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification ApproachJessica Hartmann, Barnaby Nelson, Patrick D. McGorry et al.|Frontiers in Psychiatry|2021Cited by 87
Cannabidiol for Treatment-Resistant Anxiety Disorders in Young PeopleMaximus Berger, G. Paul Amminger, Lei Li et al.|The Journal of Clinical Psychiatry|2022Cited by 73